Artesunate/pyronaridine: Difference between revisions
Bon courage (talk | contribs) →Research for drug repurposing: trim unreliable cruft, but use the one WP:MEDRS source that was present |
m Adding "update inline" template for Cochrane reference |
||
| Line 51: | Line 51: | ||
Artesunate/pyronaridine is used for [[malaria]] of both the ''[[P. falciparum]]'' and ''[[P. vivax]]'' types.<ref name=WHO2010/> It is not recommended for severe disease.<ref name=EMA2017/> |
Artesunate/pyronaridine is used for [[malaria]] of both the ''[[P. falciparum]]'' and ''[[P. vivax]]'' types.<ref name=WHO2010/> It is not recommended for severe disease.<ref name=EMA2017/> |
||
A 2019 review found that the combination compared well to [[artemether/lumefantrine]].<ref name=Pry2019>{{cite journal | vauthors = Pryce J, Hine P | title = Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD006404 | date = January 2019 | pmid = 30620055 | pmc = 6353203 | doi = 10.1002/14651858.CD006404.pub3 }}</ref> Benefits also appear similar to [[mefloquine]] together with [[artesunate]].<ref name=Pry2019 /> It is not recommended for the prevention of malaria.<ref name=EMA2017/> |
A 2019 review found that the combination compared well to [[artemether/lumefantrine]].<ref name=Pry2019>{{cite journal | vauthors = Pryce J, Hine P | title = Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD006404 | date = January 2019 | pmid = 30620055 | pmc = 6353203 | doi = 10.1002/14651858.CD006404.pub3 }}</ref>{{Update inline|reason=Updated version https://www.ncbi.nlm.nih.gov/pubmed/35726133|date = July 2022}} Benefits also appear similar to [[mefloquine]] together with [[artesunate]].<ref name=Pry2019 /> It is not recommended for the prevention of malaria.<ref name=EMA2017/> |
||
== Research for drug repurposing == |
== Research for drug repurposing == |
||
Revision as of 00:36, 2 July 2022
| Combination of | |
|---|---|
| Artesunate | Antimalarial |
| Pyronaridine | Antimalarial |
| Clinical data | |
| Trade names | Pyramax[1] |
| Other names | Artesunate/pyronaridine tetraphosphate[1] |
| Routes of administration | By mouth[2] |
| ATC code | |
| Identifiers | |
| CAS Number | |
Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed-dose combination medication for the treatment of malaria.[3][1] It can be used for malaria of both the P. falciparum and P. vivax types.[1] It combines artesunate and pyronaridine.[3] It is taken by mouth.[2]
The combination is generally well tolerated.[1] Side effects may include headache, vomiting, or cough.[1] Use in those with severe liver disease or kidney disease is not recommended.[2] Use is not generally recommended in early pregnancy.[2] However, there are no other options and if treatment may save the mother's life it may be used.[2] The two components work by different mechanisms.[2]
It is on the World Health Organization's List of Essential Medicines.[3]
Medical uses
Artesunate/pyronaridine is used for malaria of both the P. falciparum and P. vivax types.[1] It is not recommended for severe disease.[2]
A 2019 review found that the combination compared well to artemether/lumefantrine.[4][needs update] Benefits also appear similar to mefloquine together with artesunate.[4] It is not recommended for the prevention of malaria.[2]
Research for drug repurposing
There is some in vitro evidence that suggests artesunate/pyronaridine may be worthy of clinical trial study to determine whether it might have a role as a drug for COVID-19 treatment.[5]
References
- ^ a b c d e f g "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
- ^ a b c d e f g h "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
- ^ a b c World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b Pryce J, Hine P (January 2019). "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews. 1: CD006404. doi:10.1002/14651858.CD006404.pub3. PMC 6353203. PMID 30620055.
- ^ Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, Kamarulzaman A, Sall A, Kremsner P (January 2021). "Repurposing Antimalarials to Tackle the COVID-19 Pandemic". Trends Parasitol. 37 (1): 8–11. doi:10.1016/j.pt.2020.10.003. PMC 7572038. PMID 33153922.
